TTrialPathMatch Me to Trials
← Back to trials
RecruitingIdiopathic Pulmonary FibrosisEmphysema or COPD

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Eligible age

18–60 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

Sponsor: Paul Szabolcs

You may qualify if…

  • ✓ Individuals must meet all of the following criteria in order to be eligible for this study.
  • ✓ 1. Subject must be able to understand and provide informed consent.
  • ✓ 2. Male or female, 18 through 60 years old, inclusive, at the time of informed consent.
  • ✓ 3. Meet criteria for UNOS listing for lung transplantation.
  • ✓ 4. Patients must have evidence of end stage lung disease. Examples of such diseases include but are not limited to:
  • ✓ Pulmonary Fibrosis
  • ✓ COPD/Emphysema
  • ✓ 5. Patients must have evidence of bone marrow failure with abnormal low cell count in at least one hematopoietic line, making the patient a poor candidate for long-term immunosuppressive therapy. Eligible patients must meet at least one of the following criteria:

You may not qualify if…

  • ✕ Individuals who meet any of these criteria are not eligible for this study.
  • ✕ 1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
  • ✕ 2. Patients who have underlying malignant conditions.
  • ✕ 3. Patients who have non-malignant conditions not requiring BMT.
  • ✕ 4. HIV positive by serology or PCR, HTLV positive by serology. If HTLV serology is positive, it will be confirmed by nucleic acid testing (NAT). If HTLV NAT is negative, subject will remain eligible regardless of HTLV serology result.
  • ✕ 5. Females who are pregnant or who are lactating.
  • ✕ 6. Allergy to DMSO or any other ingredient used in the manufacturing of the stem cell product.
  • ✕ 7. Uncontrolled pulmonary infection, as determined by radiographic findings and/or significant clinical deterioration. NOTE: Pulmonary colonization with multiple organisms is common and will not be considered an exclusion criterion.

Where it's recruiting

Pennsylvania

Pittsburgh

Source: ClinicalTrials.gov · NCT03500731 · last updated 2026-01-13